findmyKOL
Clinical trialNCT03914742CompletedPhase 1/PHASE2Interventional

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations

SponsorSidney Kimmel Comprehensive Cancer Center at Johns HopkinsEnrollment67IDH1 MutationIDH2 MutationRecurrent GlioblastomaRecurrent WHO Grade II GliomaRecurrent WHO Grade III Glioma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This phase I/II trial studies the side effects and how well BGB-290 and temozolomide work in treating patients with gliomas (brain tumors) with IDH1/2 mutations that have come back. BGB-290 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BGB-290 and temozolomide may work better in treating patients with recurrent gliomas.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

12 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Uab Comprehensive Cancer Center

    Birmingham, Alabama, United States

  • University of California, Los Angeles

    Los Angeles, California, United States

  • Yale University

    New Haven, Connecticut, United States

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

    Baltimore, Maryland, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, United States

  • Josephine Ford Cancer Center at Henry Ford Hospital

    Detroit, Michigan, United States

  • Washington University

    St Louis, Missouri, United States

  • Wake Forest University Comprehensive Cancer Center

    Winston-Salem, North Carolina, United States

  • Cleveland Clinic Taussig Cancer Center

    Cleveland, Ohio, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, United States

  • Hillman Cancer Center at University of Pittsburgh Cancer Institute

    Pittsburgh, Pennsylvania, United States

  • University of Virginia

    Charlottesville, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PARP Inhibitor BGB-290Temozolomide →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
16 Feb 2020
Primary completion
31 Oct 2023
Completion
31 Oct 2023
Last update posted
14 Jan 2025
Registered enrollment
67
Registry id
NCT03914742
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.